These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10905487)

  • 1. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
    Buchanan TA; Xiang AH; Peters RK; Kjos SL; Berkowitz K; Marroquin A; Goico J; Ochoa C; Azen SP
    Diabetes; 2000 May; 49(5):782-8. PubMed ID: 10905487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
    Buchanan TA; Xiang AH; Peters RK; Kjos SL; Marroquin A; Goico J; Ochoa C; Tan S; Berkowitz K; Hodis HN; Azen SP
    Diabetes; 2002 Sep; 51(9):2796-803. PubMed ID: 12196473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
    Cavaghan MK; Ehrmann DA; Byrne MM; Polonsky KS
    J Clin Invest; 1997 Aug; 100(3):530-7. PubMed ID: 9239399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.
    Xiang AH; Peters RK; Kjos SL; Goico J; Ochoa C; Marroquin A; Tan S; Hodis HN; Azen SP; Buchanan TA
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2846-51. PubMed ID: 15181067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
    Antonucci T; Whitcomb R; McLain R; Lockwood D; Norris RM
    Diabetes Care; 1997 Feb; 20(2):188-93. PubMed ID: 9118772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
    Schuster D; Gaillard T; Rhinesmith S; Habash D; Osei K
    Metabolism; 2003 Sep; 52(9):1211-7. PubMed ID: 14506629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
    Prigeon RL; Kahn SE; Porte D
    J Clin Endocrinol Metab; 1998 Mar; 83(3):819-23. PubMed ID: 9506734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
    Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
    N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis.
    Zhang B; Saku K; Arakawa K
    Metabolism; 1997 Mar; 46(3):273-81. PubMed ID: 9054469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
    Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
    Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of troglitazone on insulin sensitivity.
    Henry RR
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troglitazone ameliorates insulin resistance in patients with Werner's syndrome.
    Izumino K; Sakamaki H; Ishibashi M; Takino H; Yamasaki H; Yamaguchi Y; Chikuba N; Matsumoto K; Akazawa S; Tokuyama K; Nagataki S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2391-5. PubMed ID: 9253306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is troglitazone a real indication for obese subjects with impaired glucose tolerance?
    Yoshioka K; Yokoo S; Yoshida T; Kondo M
    Diabetes Care; 1997 Aug; 20(8):1340-1. PubMed ID: 9250469
    [No Abstract]   [Full Text] [Related]  

  • 16. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
    Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
    Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
    Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP; Yu JG; Kruszynska YT; Olefsky JM
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.